The Role of Aryl Hydrocarbon Receptor in Proliferation and EMT Induction in Neuroblastoma Cancer Cells (SH-SY5Y)
Iranian Journal of Pharmaceutical Sciences,
Vol. 22 No. 1 (2026),
26 January 2026
,
Page 102-108
https://doi.org/10.22037/ijps.v22i1.50204
Abstract
Neuroblastoma is a common and aggressive cancer in children characterized by metastasis and uncontrolled cell proliferation. The Aryl Hydrocarbon Receptor (AhR) is a crucial regulator of diverse biological processes, such as cell growth, immune responses, and metabolism. However, its role in neuroblastoma progression is inadequately investigated. SH-SY5Y neuroblastoma cells were treated with the AhR antagonist CH223191, the agonist benzo[a]pyrene (BaP), and the endogenous ligand 6-Formylindolo[3,2-b]carbazole (FICZ). Cell viability was evaluated by MTT assay, and ROS levels were measured by dichlorofluorescein (DCF) assay, while EMT-related gene expression (vimentin and E-cadherin) was analyzed using qPCR. Compared to control, treatment with CH223191 and BaP significantly decreased cell viability and increased ROS production, respectively. BaP induced a greater reduction in viability and increase in ROS than FICZ (p < 0.01). Gene expression analysis revealed that CH223191 and BaP decreased vimentin expression (p < 0.05 and p < 0.001) and increased E-cadherin expression (p < 0.05 and p < 0.001), indicating the inhibition of EMT and promotion of epithelial characteristics. These findings highlight the pivotal role of AhR in modulating proliferation, mitochondrial function, and EMT in neuroblastoma cells, indicating that targeting AhR signaling may offer a novel therapeutic strategy to impede neuroblastoma progression and metastasis.
- Neuroblastoma
- Aryl Hydrocarbon Receptor
- Proliferation
- ROS
- EMT
How to Cite
References
1. Maris JM. Recent advances in neuroblastoma. New England Journal of Medicine. 2010;362(23):2202-11.
2. Katta SS, Nagati V, Paturi ASV, Murakonda SP, Murakonda AB, Pandey MK, et al. Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets. Journal of Controlled Release. 2023;357:444-59.
3. Nong J, Su C, Li C, Wang C, Li W, Li Y, et al. Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYs. EClinicalMedicine. 2025;79.
4. Wu P-Y, Yu I-S, Lin Y-C, Chang Y-T, Chen C-C, Lin K-H, et al. Activation of aryl hydrocarbon receptor by kynurenine impairs progression and metastasis of neuroblastoma. Cancer research. 2019;79(21):5550-62.
5. Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV. Neuroblastoma origin and therapeutic targets for immunotherapy. Journal of immunology research. 2018;2018(1):7394268.
6. Sharma R, Yadav J, Bhat SA, Musayev A, Myrzagulova S, Sharma D, et al. Emerging trends in neuroblastoma diagnosis, therapeutics, and research. Molecular Neurobiology. 2025;62(5):6423-66.
7. Hankinson O. The aryl hydrocarbon receptor complex. Annual review of pharmacology and toxicology. 1995;35:307-40.
8. Shadboorestan A, Koual M, Dairou J, Coumoul X. The role of the kynurenine/AhR pathway in diseases related to metabolism and cancer. International Journal of Tryptophan Research. 2023;16:11786469231185102.
9. Shadboorestan A, Tarfiei GA, Montazeri H, Sepand MR, Zangooei M, Khedri A, et al. Invasion and migration of MDA-MB-231 cells are inhibited by block of AhR and NFAT: role of AhR/NFAT1/β4 integrin signaling. J Appl Toxicol. 2019;39(2):375-84.
10. Chaudhry KA, Jacobi JJ, Gillard BM, Karasik E, Martin JC, da Silva Fernandes T, et al. Aryl hydrocarbon receptor is a tumor promoter in MYCN-amplified neuroblastoma cells through suppression of differentiation. iScience. 2023;26(11):108303.
11. Chaudhry KA, Bianchi-Smiraglia A. The aryl hydrocarbon receptor as a tumor modulator: mechanisms to therapy. Front Oncol. 2024;14:1375905.
12. Jahangiri L. Epithelial to Mesenchymal Transition in Neuroblastoma: Mechanisms and Therapeutic Considerations. Current Tissue Microenvironment Reports. 2024;5(4):91-108.
13. Shao JB, Gao ZM, Huang WY, Lu ZB. The mechanism of epithelial-mesenchymal transition induced by TGF-β1 in neuroblastoma cells. Int J Oncol. 2017;50(5):1623-33.
14. Congues F, Wang P, Lee J, Lin D, Shahid A, Xie J, Huang Y. Targeting aryl hydrocarbon receptor to prevent cancer in barrier organs. Biochem Pharmacol. 2024;223:116156.
15. Mulero-Navarro S, Fernandez-Salguero PM. New Trends in Aryl Hydrocarbon Receptor Biology. Front Cell Dev Biol. 2016;4:45.
16. Wincent E, Amini N, Luecke S, Glatt H, Bergman J, Crescenzi C, et al. The Suggested Physiologic Aryl Hydrocarbon Receptor Activator and Cytochrome P4501 Substrate 6-Formylindolo[3,2-b]carbazole Is Present in Humans. Journal of Biological Chemistry. 2009;284(5):2690-6.
17. Wei Y-D, Bergander L, Rannug U, Rannug A. Regulation of CYP1A1 Transcription via the Metabolism of the Tryptophan-Derived 6-Formylindolo[3,2-b]carbazole. Archives of Biochemistry and Biophysics. 2000;383(1):99-107.
18. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochemical Pharmacology. 2000;59(1):65-85.
19. Bock KW. Aryl hydrocarbon receptor (AHR): From selected human target genes and crosstalk with transcription factors to multiple AHR functions. Biochem Pharmacol. 2019;168:65-70.
20. Dean JW, Zhou L. Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity. Trends Immunol. 2022;43(3):245-58.
21. John K, Lahoti TS, Wagner K, Hughes JM, Perdew GH. The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines. Mol Carcinog. 2014;53(10):765-76.
22. Brooks J, E. Eltom S. Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. Current cancer drug targets. 2011;11(5):654-69.
23. Wang Z, Snyder M, Kenison JE, Yang K, Lara B, Lydell E, et al. How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression. International Journal of Molecular Sciences. 2021;22(1):387.
24. Wu PY, Liao YF, Juan HF, Huang HC, Wang BJ, Lu YL, et al. Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma. PLoS One. 2014;9(2):e88795.
- Abstract Viewed: 118 times
- IJPS_Volume22_Issue1_Pages102-108 Downloaded: 74 times